Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rivaroxaban

FDA-approved product (tablet, oral), marketed as Rivaroxaban, Xarelto.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rivaroxaban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Atrial fibrillation
  • Coronary artery disease
  • Deep vein thrombosis
  • Peripheral arterial disease
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Total joint arthroplasty
  • Venous thromboembolism
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
FDA pharmacologic class
Factor Xa Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rivaroxaban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rivaroxaban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

    NCT02833948 · start 2016-05

    Registered record
    Registry ID
    NCT02833948
    Conditions
    Aortic Valve Stenosis; Cardiovascular Diseases; Heart Valve Diseases; Ventricular Outflow Obstruction; Thrombosis
    Interventions
    Acetylsalicylic acid; Clopidogrel; Rivaroxaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05
    Completion
    2019-03-06
    Enrolment
    231

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Valve Stenosis; Cardiovascular Diseases; Heart Valve Diseases; Ventricular Outflow Obstruction +1 more
    InterventionAcetylsalicylic acid; Clopidogrel; Rivaroxaban
    PhasePhase 3
    Registry statusCompleted

  • Atrial Fibrillation Patient Preference Study

    NCT02611635 · start 2016-02-02

    Registered record
    Registry ID
    NCT02611635
    Conditions
    Atrial Fibrillation
    Interventions
    VKA: Warfarin (Waran); NOAC: Rivaroxaban (Xarelto, BAY59-7939); NOAC: Dabigatran etexilate; NOAC: Apixaban; NOAC: Edoxaban; NOAC: Lixiana
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-02-02
    Completion
    2017-02-16
    Enrolment
    382

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionVKA: Warfarin (Waran); NOAC: Rivaroxaban (Xarelto, BAY59-7939); NOAC: Dabigatran etexilate; NOAC: Apixaban +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Pleotropic Effect of New Oral Anticoagulants

    NCT02544932 · start 2015-10

    Registered record
    Registry ID
    NCT02544932
    Conditions
    Atrial Fibrillation
    Interventions
    dabigatran; ribaroxaban; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2017-09
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventiondabigatran; ribaroxaban; Warfarin
    PhasePhase 3
    Registry statusUnknown

  • A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

    NCT02555878 · start 2015-09-11

    Registered record
    Registry ID
    NCT02555878
    Conditions
    Neoplasms
    Interventions
    Rivaroxaban; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09-11
    Completion
    2018-08-24
    Enrolment
    841

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionRivaroxaban; Placebo
    PhasePhase 3
    Registry statusCompleted

  • ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

    NCT02935855 · start 2015-09

    Registered record
    Registry ID
    NCT02935855
    Conditions
    Diabetes
    Interventions
    Dabigatran; Apixaban; Rivaroxaban; Edoxaban; Warfarin; Acenocumarole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionDabigatran; Apixaban; Rivaroxaban; Edoxaban +2 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

    NCT02561923 · start 2015-08-27

    Registered record
    Registry ID
    NCT02561923
    Conditions
    Healthy
    Interventions
    Rivaroxaban; Tranexamic acid; Kcentra, a 4-factor PCC; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-08-27
    Completion
    2016-06-17
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRivaroxaban; Tranexamic acid; Kcentra, a 4-factor PCC; Saline
    PhasePhase 1
    Registry statusCompleted

  • Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation

    NCT02814955 · start 2015-06

    Registered record
    Registry ID
    NCT02814955
    Conditions
    Atrial Fibrillation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-06
    Completion
    2017-09
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Real-Life Evidence on Stroke Prevention in SPAF

    NCT02485873 · start 2015-05

    Registered record
    Registry ID
    NCT02485873
    Conditions
    Atrial Fibrillation (Prevention of Stroke)
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Vitamin K antagonists
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-09
    Enrolment
    8,607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (Prevention of Stroke)
    InterventionRivaroxaban (Xarelto, BAY59-7939); Vitamin K antagonists
    PhaseNot recorded
    Registry statusCompleted

  • Direct Oral Anticoagulants and Venous Thromboembolism

    NCT02833987 · start 2015-03

    Registered record
    Registry ID
    NCT02833987
    Conditions
    Venous Thromboembolism; Major Bleed
    Interventions
    Apixaban (ATC B01AF02); Dabigatran (ATC B01AE07); Rivaroxaban (ATC B01AF01); Warfarin (ATC B01AA03)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-03
    Completion
    2015-03
    Enrolment
    59,525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism; Major Bleed
    InterventionApixaban (ATC B01AF02); Dabigatran (ATC B01AE07); Rivaroxaban (ATC B01AF01); Warfarin (ATC B01AA03)
    PhaseNot recorded
    Registry statusCompleted

  • Periprocedural Direct Oral Anticoagulant Management

    NCT03182218 · start 2015-02

    Registered record
    Registry ID
    NCT03182218
    Conditions
    Periprocedural Complication
    Interventions
    Direct oral anticoagulant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-02
    Completion
    2018-06
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriprocedural Complication
    InterventionDirect oral anticoagulant
    PhaseNot recorded
    Registry statusCompleted

  • EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

    NCT02234843 · start 2014-11-13

    Registered record
    Registry ID
    NCT02234843
    Conditions
    Venous Thromboembolism
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-11-13
    Completion
    2019-01-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionRivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    PhasePhase 3
    Registry statusCompleted

  • Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia

    NCT02260622 · start 2014-10

    Registered record
    Registry ID
    NCT02260622
    Conditions
    Critical Limb Ischemia
    Interventions
    rivaroxaban plus aspirin; clopidogrel plus aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-10
    Completion
    2019-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Limb Ischemia
    Interventionrivaroxaban plus aspirin; clopidogrel plus aspirin
    PhasePhase 2
    Registry statusCompleted

  • A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

    NCT02220725 · start 2014-05

    Registered record
    Registry ID
    NCT02220725
    Conditions
    Bleeding
    Interventions
    Andexanet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBleeding
    InterventionAndexanet; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists

    NCT01722786 · start 2014-04

    Registered record
    Registry ID
    NCT01722786
    Conditions
    Severe Bleeding; Urgent Surgery
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-04
    Completion
    2019-07-09
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Bleeding; Urgent Surgery
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).

    NCT01871194 · start 2013-05

    Registered record
    Registry ID
    NCT01871194
    Conditions
    Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-05
    Completion
    2017-09
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted